Literature DB >> 2420476

Immunological problems of polymer-bound drugs.

B Rihova, I Riha.   

Abstract

For the application of polymer-bound drugs (especially in combination with the targeting antibodies), it is essential to know more about the immunogenicity and possible hazards from immune reactions induced by their repeated application. The immune reaction depends on many factors (including structure of antigen, dose of antigen, schedule and way of the application, genetic background of the immunized, i.e., receiving organism) and could be weakened or eliminated by a choice of suitable factors. Problems connected with the immune reaction of the humoral and cellular type (B and T cell involvement) against different polymers and polymer-bound drugs and possible consequences for their clinical use will be discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2420476

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  4 in total

1.  Advances of cancer therapy by nanotechnology.

Authors:  Xu Wang; Yiqing Wang; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

Review 2.  Antibody-targeted polymer-bound drugs.

Authors:  B Ríhová
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators.

Authors:  D Derrien; P Midoux; C Petit; E Nègre; R Mayer; M Monsigny; A C Roche
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Perspectives on clinical translation of smart nanotherapeutics.

Authors:  Joyce Lee; Kit S Lam
Journal:  Ther Deliv       Date:  2012-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.